Growth That Masks Its Own Weaknesses
Revenue soared 20% YoY and PAT jumped 39%, but margins compressed below guidance, operating cash flow collapsed 82% quarter-on-quarter, and the company's key growth initiatives fell behind targets. The gap between the headline and what lies beneath is the real story.
₹1,560 Cr
+20.3% YoY, +5.6% QoQ
₹181.8 Cr
+39.2% YoY, +1.0% QoQ
21.6%
vs. 22–23% guidance; −131 bps QoQ
₹65 Cr
vs. ₹387 Cr Q1; −82% QoQ
The Tension: Headline Growth, Execution Slippages
Granules delivered textbook growth — revenue at ₹1,560 Cr and profit at ₹181.8 Cr both crushed prior-year comps by 20% and 39% respectively, marking the eighth consecutive quarter of sequential revenue expansion. On the surface, a clean story. But the call revealed a different quarter underneath: EBITDA margins compressed to 21.6%, 131 basis points below the prior guidance range of 22–23%, PAT growth decelerated to just 1% quarter-on-quarter despite 5.6% revenue growth, and operating cash flow collapsed to ₹65 Cr from ₹387 Cr in Q1 — an 82% decline. Management's tone was confident, but the numbers tell a story of cost pressures, working capital absorption, and delayed commercialization of key strategic initiatives.
Management's Claims: What Held Up, What Didn't
Revenue grew 20% YoY to ₹1,560 Cr, crossing ₹1,500 Cr for first time
Supported₹1,560 Cr, +20.3% YoY
PAT increased 39% to ₹181.8 Cr
Supported₹181.8 Cr, +39.2% YoY
EBITDA margins expected to sustain 22–23% range
Missed21.6%, down 131 bps QoQ
Operating cash flow positive; business fundamentals strong
Contradicted₹65 Cr (Q2) vs. ₹387 Cr (Q1); 82% decline
Peptide CDMO to be PAT positive on annual basis by FY27 end
OverstatedH2 revenue ₹109 Cr vs. ₹240 Cr minimum target; cumulative EBITDA loss ₹28 Cr
Gross margins remain healthy despite input cost inflation
OverstatedGross margin 64.4%, down 134 bps YoY and 126 bps QoQ
FDA observations addressable; no business impact
PartialForm 483 with 11 observations (process, control, documentation); 15-day response window
What Changed This Quarter
Margin guidance slipped for the first time: prior commentary promised 22–23% EBITDA margins would persist, but delivered 21.6%, a shortfall the company attributed to West Asia conflict-driven freight and input cost escalation. Capex trajectory was sharply raised, with management outlining ₹2,000 Cr of planned capex over the next 3–4 years (versus prior ₹600 Cr FY27 guidance) — Q1 and Q2 combined have already deployed ₹219.4 Cr. Peptide CDMO commercialization slowed notably: H2 revenue was projected at only ₹109 Cr, far short of the minimum ₹240 Cr annual target, and the division remains loss-making with cumulative EBITDA losses of ₹28 Cr. On the positive side, complex generics now represent 47% of the formulations portfolio (up from 46% prior quarter), signaling a deliberate strategic pivot away from legacy API commoditization, and 26 FDA approvals remain pending with 5 product launches planned in Q3 and Q4. FDA approval risk emerged as a genuine near-term overhang: Gagillapur facility received a Form 483 with 11 observations (process control, recruitment, documentation issues), requiring a 15-day response.
Where the Profit Weakness Came From
PAT growth of 39% YoY masks a profitability squeeze. While revenue grew 20% YoY, EBITDA margin compression of 131 basis points quarter-on-quarter meant PAT expanded only 1% sequentially — the operating leverage broke. Gross margin fell 134 basis points YoY to 64.4%, driven by input cost inflation and West Asia conflict-related freight escalation. Concurrently, operating cash flow deteriorated sharply. Working capital surged to 30% of sales (from 29% Q1), with inventory buildup cited as deliberate for safety stock and controlled-substances capacity support. Capex deployed at ₹130 Cr in Q2 added to the cash drag. The combined effect: cash generated from operations collapsed from ₹387 Cr in Q1 to ₹65 Cr in Q2, a reversal that management characterized as 'H1 level' absorption but analysts challenged as unsustainable.
Eight consecutive quarters of sequential growth validates core business momentum
Complex generics now 47% of portfolio; strategic repositioning away from commodity API reduces cyclicality
26 pending FDA approvals and 5 launches (Q3–Q4) provide near-term revenue catalysts
Net cash position of ₹828 Cr provides firepower for ₹2,000 Cr capex and acquisition optionality
PAT growth of 39% YoY and crossing ₹1,500 Cr revenue milestone cement market leadership in formulations
EBITDA margin guidance missed; delivered 21.6% vs. 22–23% prior range — first guidance slippage
Operating cash flow collapsed 82% QoQ; working capital at 30% of sales unsustainable
Peptide CDMO significantly behind targets (₹109 Cr H2 vs. ₹240 Cr minimum); PAT profitability by FY27 end at risk
FDA Form 483 with 11 observations; 15-day response creates near-term regulatory uncertainty
Management offered only vague forward guidance ('we don't give guidance'); multiple redirects on CDMO customer wins and capex contingency
Margin compression and cash flow deterioration
HighGross margin down 134 bps YoY, EBITDA margin down 131 bps QoQ, and operating cash flow collapsed 82% QoQ. PAT growth of only 1% QoQ despite 5.6% revenue growth signals the operating leverage has reversed. If cost pressures persist or West Asia disruption extends, margin recovery is uncertain.
Working capital absorption and cash conversion quality
HighOperating cash flow of ₹65 Cr (Q2) vs. ₹387 Cr (Q1) is a red flag. Management frames it as temporary and Q1–Q2 together for capex/WC absorption, but inventory at 30% of sales and capex at ₹130 Cr Q2 suggest cash conversion may structurally weaken as capex ramps.
Peptide CDMO commercialization slippage
MediumH2 revenue of ₹109 Cr falls far short of the ₹240 Cr minimum annual target. The division remains loss-making (cumulative EBITDA loss ₹28 Cr). Management's 'PAT profitability by FY27 end' commitment is at risk. CDMO partnerships (2 major players) suggest execution challenges.
FDA Form 483 and remediation uncertainty
Medium11 observations at Gagillapur (process, control, documentation). While management downplays severity and the dialogue is described as positive, 15-day response window and FDA discretion on re-inspection create genuine near-term uncertainty. GGP is ~75% utilized; further disruption could impact product launches.
Capex intensity and ROCE dilution
Medium₹2,000 Cr capex planned over 3–4 years will strain near-term margins and ROE. Consolidated ROCE already at 17.6% (Genome Valley at 25%, Peptide CDMO loss-making). Large capex deployment may further dilute returns before new capacity is absorbed.
Guidance avoidance and management credibility
Low-MediumManagement repeatedly declined to provide numeric revenue or margin guidance despite direct analyst requests, citing 'we don't give guidance.' Also deflected on CDMO customer wins (~$200M target) citing confidentiality. Suggests either low confidence in near-term trajectory or structural shift in communication policy.
How the Street Is Positioned
Price action and valuation context: The stock trades at ₹794.45 (as of Nov 5), down 13.92% from its all-time high of ₹922.95 but well-supported, sitting +49.94% above its 52-week low. Relative to moving averages, it trades below the 20-day (₹814.32) and 50-day (₹838.92) but above the 200-day (₹742.65), suggesting a loss of momentum but not a breakdown. RSI of 40.3 is neutral. Volume trend is increasing, signaling emerging demand at these levels. The post-result price action verdict: The market has not yet digested the margin miss and cash flow weakness; the stock's positioning suggests institutional investors are still evaluating whether the growth narrative overcomes near-term execution headwinds.
Ownership and flows: FII ownership rose sharply to 17.50% from 15.31% in Q4 FY26, a +2.19 percentage-point increase, signaling FII confidence in the growth trajectory. Conversely, DII trimmed holdings to 16.11% from 17.01%, down 0.9pp — domestic institutions may be cautious on the margin trajectory. Promoter holdings remain stable at 38.02%, unchanged. FLAG: In early September 2026, promoter Krishna Prasad Chigurupati executed a block sale of 1,32,95,129 shares at ₹872.50 per share (near the ATH), raising approximately ₹116 Cr. Simultaneously, large institutional buyers (BNP Paribas Financial Markets, Goldman Sachs, Capital Group, Smallcap World Fund) accumulated ₹2,000+ Cr notional at the same price. The timing (near ATH) and the size (₹116 Cr promoter sell-off concurrent with FII accumulation) warrant scrutiny — the promoter may have been reducing exposure ahead of anticipated headwinds, or simply rebalancing. Regardless, the divergence in flows signals a transition: FIIs are building, but the founding family is stepping back.
The Debate
1 · Margin recovery trajectory in Q3–Q4
Did the West Asia disruption ease? Are freight and input costs normalizing? EBITDA margin needs to stabilize toward 22% or better for operating leverage to return. Watch quarterly gross margin and EBITDA margin progression; if margins remain compressed, the capex-to-growth-to-ROCE chain breaks.
2 · Operating cash flow and working capital normalization
Q2's ₹65 Cr OCF is a red flag. Management claims it is temporary (H1 absorption). Q3–Q4 should show OCF recovery toward ₹200+Cr levels and working capital trending back to <29% of sales. If cash conversion remains weak (₹65–₹100 Cr OCF run-rate), the capex plan becomes a balance-sheet strain.
3 · FDA response and CDMO commercialization tangibles
Gagillapur's 15-day Form 483 response is due imminently (Q4). Any follow-up inspection or NAI (non-approval) would extend uncertainty and delay the 26 pending approvals. On CDMO, H2 offtake commitments and customer announcements are critical; ₹109 Cr projected revenue must be validated. Any upside to H2 CDMO revenue would restore credibility to the 'PAT positive by FY27 end' target.
Granules India delivered growth that reads well on the surface — eight consecutive quarters of sequential expansion, 20% YoY revenue growth, 39% YoY PAT growth — but the quarter revealed a company in transition, grappling with margin compression, cash flow deterioration, and strategic delays. The EBITDA margin miss (21.6% vs. 22–23% guidance), the 82% operating cash flow collapse, and the peptide CDMO slippage are not trifles; they signal real execution challenges, not just cyclical headwinds. Management's tone was confident but evasive on specifics, and the promoter's September block sale near ATH while FIIs accumulated signals diverging views on near-term trajectory.
This is not a moment for fresh conviction. It is a moment for patience. The company's core business remains sound, the complex-generics pivot is strategically sound, and the balance sheet is strong enough to fund the capex plan. But margins need to recover, cash conversion needs to normalize, and CDMO needs to show tangible progress. The single metric to track is operating cash flow — if Q3–Q4 sustains ₹65 Cr run rates, the capex thesis and ROCE assumptions break. If OCF normalizes to ₹200+Cr levels, the carry-through story holds. Until then, Hold, reassess after Q3 print and FDA Form 483 response.
Informational and educational content only. Not investment advice.